Gastric Cancer

P2/3, N=840, Recruiting, Pfizer | Not yet recruiting --> Recruiting

P1, N=13, Terminated, Zhejiang Doer Biologics Co., Ltd. | N=94 --> 13 | Trial completion date: Jun 2025 --> Mar 2026 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Dec 2025; This trial was terminated voluntarily by the Sponsor for reasons related to its corporate strategic development, with no safety concerns or efficacy signals related to the investigational product identified.

P1, N=383, Recruiting, Iambic Therapeutics, Inc | N=243 --> 383 | Trial completion date: Mar 2028 --> Dec 2028 | Trial primary completion date: Mar 2027 --> Dec 2027

P1, N=158, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Apr 2027

In conclusion, our integrated computational study provides preliminary evidence suggesting ESR1 as a potential hub linking BaP exposure to gastric cancer risk, possibly via influencing immune features. This identifies ESR1 as a candidate biomarker and reveals a testable hypothesis for future mechanistic investigation.

Compared with minimally invasive-assisted Billroth-II distal gastrectomy, totally minimally invasive Billroth-II distal gastrectomy is a feasible and safe radical operation with acceptable surgical outcomes that may offer shorter post-operative recovery times.

In vivo experiments further confirmed that the SNHG15/miR-451a/CAV1 axis affected gastric cancer oxaliplatin resistance by regulating fatty acid β-oxidation. Implications: This study revealed that SNHG15 inhibits miR-451a to upregulate CAV1 expression, thereby regulating fatty acid β-oxidation and influencing gastric cancer oxaliplatin resistance, providing new biomarkers and potential therapeutic targets for gastric cancer oxaliplatin resistance.

Moreover, we uncover that TGF-β1-induced miR-135b-5p downregulates DTX3L, forming a regulatory axis that promotes EMT. Collectively, our findings reveal a novel DTX3L-SNAI1 signaling pathway governing EMT and metastasis in gastric cancer, providing mechanistic insight and suggesting DTX3L as a potential prognostic biomarker and therapeutic target.

Therefore, when creating animal models with xenografted tumors, it is important to understand the angiogenic potential of cancer cells, especially for studying drug candidates with an antiangiogenic effect. Also, the combination of optoacoustics and immunohistochemical analysis with FLIM imaging allows for a comprehensive assessment of both vascularization and the metabolic state of the tumor, which can help predict the therapeutic response.

Hematoxylin-eosin, immunohistochemistry, and immunofluorescence staining revealed that FOSB and LDHC have strong recognition abilities for GHGIN. FOSB and LDHC are pivotal biomarkers for GHGIN transformation, highlighting their potential as targets for GC diagnosis and treatment.

FOLH1 may be involved in tumor progression by regulating amino acid metabolic pathways and the immune microenvironment. It is a promising pan-cancer prognostic marker and synergistic target for immunotherapy.

Despite significant advances, challenges persist-including tumor heterogeneity, immunosuppressive TME, and the need to balance therapeutic efficacy with toxicity. Future directions should leverage multi-omics and artificial intelligence to optimize personalized combination therapies, advance precise perioperative interventions for early-stage GC, and implement dynamic treatment adjustments, ultimately improving therapeutic efficacy and patient outcomes.